Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.
Their findings, published recently in the journal Neuron, focus on M4, a subtype of the muscarinic acetylcholine family of nerve cell (neuron) receptors activated by binding the neurotransmitter acetylcholine.
